Development of reference material for blood tumor mutational burden measurement
Determining and using the most effective and safest treatment is of great importance in cancer disease management. Recently, a potential biomarker has been identified in immunotherapy: tumor mutational burden (TMB), an assessment of the number of relevant mutations in a tumor.
Although most TMB measurements are made from genomic DNA that has been extracted from formalin-fixed paraffin embedded tissue sections, some diagnostic tests attempt to measure TMB in circulating tumor DNA (ctDNA) extracted from blood samples; an approach referred to as blood TMB (bTMB). bTMB is an attractive biomarker since it has the potential to bypass many of the obstacles encountered with resected and hard to biopsy tumors. Download this free poster to learn about how we developed our reference material for blood tumor mutational burden measurement. Fill out the form to download our free poster.
Fill out the form to download our free poster.